HCMV stimulation of interferon signaling to promote viral gene expression and latency
Project Number1F32AI186281-01
Contact PI/Project LeaderWHITE, TIMOTHY M
Awardee OrganizationUNIVERSITY OF ARIZONA
Description
Abstract Text
Project Summary
Human cytomegalovirus (HCMV) is a ubiquitous and medically significant pathogen which causes severe
morbidity and mortality among immunocompromised populations. HCMV, a betaherpesvirus, enters lifelong
quiescent persistence in the infected host known as latency. Latency is very complex but is known to require
the participation of both host and viral factors, and inhibition of either can lead to a loss of latency in ex vivo
model systems. HCMV specifically co-opts innate cellular antiviral signaling via the interferon alpha receptor
(IFNAR) signaling pathway, which leads to the activation of signal transducer and activator of transcription 1
(STAT1). STAT1 acts as a transcription factor, binding to a conserved DNA motif known as an interferon-
stimulated response element (ISRE) and initiating transcription of interferon stimulated genes (ISGs) which are
essential for antiviral defense. During normal cellular homeostasis, activated STAT1 (pSTAT1) is rapidly
dephosphorylated resulting in cessation of signaling, however, HCMV maintains STAT1 phosphorylation at
high levels through 72 hours. Maintenance of pSTAT1 during infection requires the viral protein UL138 in
complex with host UAF1 and USP1, and inhibition of these proteins prevents the establishment of latency,
suggesting that pSTAT1 signaling is essential for viral persistence. HCMV also appropriates pSTAT1 by
recruiting it to the viral genome, where it binds to viral ISRE sequences, suggesting the existence of viral ISGs.
In this proposal we seek to determine the mechanisms by which HCMV maintains STAT1 phosphorylation
during infection and the impacts of this prolonged signaling on viral replication and latency. We hypothesize
that HCMV manipulates the IFNAR1 signaling pathway to phosphorylate STAT1, thereby inducing transcription
of viral genes and promoting viral latency. Our goal is to answer two overarching questions. First, how does
HCMV maintain STAT1 signaling? We hypothesize that HCMV licenses STAT1 interaction with IFNAR by
removing inhibitory ubiquitin moieties, while simultaneously impeding sorting endosome turnover to prolong
IFNAR complex stability and signaling. Second, what is the impact of UL138-induced STAT1 signaling? We
hypothesize that STAT1 signaling is used by HCMV to regulate transcription of its own genes and to alter the
intracellular environment to promote latency. Answering these questions will provide new insight into viral and
cellular processes involved in the pathogenesis of this important human pathogen and potentially lead to novel
approaches to therapeutic or curative treatments.
Public Health Relevance Statement
Project Narrative
Human cytomegalovirus (HCMV) is a ubiquitous and medically significant pathogen which masterfully evades
and manipulates host immune responses. As part of its life cycle, HCMV enters a quiescent state known as
latency, which it accomplishes using a combination of viral and host factors. This project seeks to determine
the ways HCMV manipulates the human immune system to its own advantage, to enhance viral latency and
persistence.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
806345617
UEI
ED44Y3W6P7B9
Project Start Date
01-November-2024
Project End Date
31-October-2027
Budget Start Date
01-November-2024
Budget End Date
31-October-2025
Project Funding Information for 2024
Total Funding
$74,284
Direct Costs
$74,284
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$74,284
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1F32AI186281-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1F32AI186281-01
Patents
No Patents information available for 1F32AI186281-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1F32AI186281-01
Clinical Studies
No Clinical Studies information available for 1F32AI186281-01
News and More
Related News Releases
No news release information available for 1F32AI186281-01
History
No Historical information available for 1F32AI186281-01
Similar Projects
No Similar Projects information available for 1F32AI186281-01